{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:00:30Z","timestamp":1793048430708,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.eclinm.2025.103400","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T17:39:28Z","timestamp":1754156368000},"page":"103400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: a randomized, double-blind, placebo-controlled, multicenter phase II study"],"prefix":"10.1016","volume":"87","author":[{"given":"Chong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dachuan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guicheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuping","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5437-6028","authenticated-orcid":false,"given":"George","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103400_bib1","article-title":"Immune mechanisms underlying hepatitis b surface antigen seroclearance in chronic hepatitis b patients with viral coinfection","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103400_bib2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.gastro.2022.10.008","article-title":"Current best practice in hepatitis B management and understanding long-term prospects for cure","volume":"164","author":"Yardeni","year":"2023","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103400_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.akdh.2023.04.003","article-title":"Management of hepatitis c virus and hepatitis b virus infection in the setting of kidney disease","volume":"30","author":"Sharma","year":"2023","journal-title":"Adv Kidney Dis Health"},{"issue":"23","key":"10.1016\/j.eclinm.2025.103400_bib4","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1097\/CM9.0000000000001793","article-title":"Low-level viremia in nucleoside analog-treated chronic hepatitis B patients","volume":"134","author":"Zhang","year":"2021","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103400_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103400_bib6","first-page":"1139","article-title":"[Clinical significance and management strategies of low-level viremia during the treatment of chronic hepatitis B]","volume":"29","author":"Han","year":"2021","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103400_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11901-024-00663-6","article-title":"When to stop antiviral therapy in HBeAg-negative patients with chronic hepatitis B?","volume":"23","author":"Liaw","year":"2024","journal-title":"Current Hepatol Rep"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103400_bib8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"A ASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103400_bib9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103400_bib10","first-page":"242","article-title":"[Treat-all: challenges of partial response and low-level viremia]","volume":"31","author":"Liu","year":"2023","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"10.1016\/j.eclinm.2025.103400_bib11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.coph.2016.08.004","article-title":"Modulators of HBV capsid assembly as an approach to treating hepatitis B virus infection","volume":"30","author":"Cole","year":"2016","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103400_bib12","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","article-title":"APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients","volume":"15","author":"Kao","year":"2021","journal-title":"Hepatol Int"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103400_bib13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3748\/wjg.v27.i8.666","article-title":"New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: increase of entecavir dosage","volume":"27","author":"Yin","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103400_bib14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","article-title":"JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection","volume":"159","author":"Zoulim","year":"2020","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103400_bib15","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1136\/gutjnl-2022-328041","article-title":"Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection","volume":"72","author":"Janssen","year":"2023","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103400_bib16","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/17460441.2023.2239701","article-title":"The premise of capsid assembly modulators towards eliminating HBV persistence","volume":"18","author":"Bassit","year":"2023","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103400_bib17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12916-023-02814-w","article-title":"Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial","volume":"21","author":"Jia","year":"2023","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103400_bib18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/apt.15581","article-title":"Clinical pharmacology of current and investigational hepatitis B virus therapies","volume":"51","author":"Smolders","year":"2020","journal-title":"Aliment Pharmacol Therapeut"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103400_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01220-21","article-title":"Safety, tolerability, and pharmacokinetics of the novel hepatitis B virus capsid assembly modulator GST-HG141 in healthy Chinese subjects: a first-in-human single-and multiple-dose escalation trial","volume":"65","author":"Li","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103400_bib20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12985-024-02584-8","article-title":"Safety, pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized, placebo-controlled design","volume":"21","author":"Wu","year":"2024","journal-title":"Virol J"},{"key":"10.1016\/j.eclinm.2025.103400_bib21","first-page":"11","article-title":"Preclinical characterization of GST-HG141, a novel hepatitis B virus capsid assembly modulator","volume":"7","author":"Zhang","year":"2024","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103400_bib22","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ajg.2011.45","article-title":"Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety","volume":"106","author":"Yuen","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103400_bib23","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/liv.12343","article-title":"HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D","volume":"34","author":"Liu","year":"2014","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103400_bib24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/jcpt.12023","article-title":"Pharmacokinetics and food interaction of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy volunteers","volume":"38","author":"Lu","year":"2013","journal-title":"J Clin Pharm Therapeut"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103400_bib25","first-page":"1268","article-title":"Current status of the research on low-level viremia in chronic hepatitis B patients receiving nucleos (t) ide analogues","volume":"37","author":"Fengming","year":"2021","journal-title":"J Clin Hepatol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103400_bib26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/infdis\/jiv397","article-title":"Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues","volume":"213","author":"Jansen","year":"2016","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103400_bib27","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/infdis\/jiy270","article-title":"Serum HBV RNA as a predictor of peginterferon alfa-2a response in patients with HBeAg-positive chronic hepatitis B","volume":"218","author":"van B\u00f6mmel","year":"2018","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103400_bib28","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/liv.14786","article-title":"Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia","volume":"41","author":"Li","year":"2021","journal-title":"Liver Int"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T20:23:33Z","timestamp":1772915013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025003323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":28,"alternative-id":["S2589537025003323"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103400","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: a randomized, double-blind, placebo-controlled, multicenter phase II study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103400","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103400"}}